Ardelyx to Participate in Three Upcoming Investor Conferences in September

FREMONT, Calif., Sept. 8, 2020 /PRNewswire/ -- Ardelyx, Inc. ARDX, a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Ardelyx management will participate in three upcoming investor conferences in September including:

• Citi's 15^th Annual BioPharma Virtual Conference on Wednesday, September 9^th
• 22nd Annual H.C. Wainwright Global Investment Conference on Monday, September 14^th with a presentation at 5:00 p.m. E.T.
• Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday, September 17^th with a presentation at 12:40 p.m. E.T.

Both the H.C. Wainwright and Cantor Fitzgerald conference presentations will be available via webcast. To access the live webcasts of Ardelyx's presentations, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcasts will be available on the Ardelyx website for 30 days following each conference.

About Ardelyx, Inc.
Ardelyx is a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases. The Ardelyx pipeline includes tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, for which an NDA is under review by the FDA, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA^® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

SOURCE Ardelyx